Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | EDNRA | P25101 | 1/20 | 0.69 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | TOP1 | P11387 | 3/20 | 0.51 |
| ▸ | DPP4 | P27487 | 5/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esafloxacin SCHEMBL1231132 | 0.99 | LMNA (0.68) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL10677290 | 0.92 | LMNA (0.71) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9044893 | 0.90 | KMT2A (0.67) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9437345 | 0.89 | LMNA (0.67) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Hydrochloric Acid SCHEMBL10669137 | 0.88 | LMNA (0.66) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9437381 | 0.88 | LMNA (0.66) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9437379 | 0.88 | LMNA (0.66) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL11165875 | 0.87 | LMNA (0.67) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9437352 | 0.86 | LMNA (0.72) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Hydrochloric Acid SCHEMBL10658429 | 0.86 | LMNA (0.66) | LMNACYP2C9ATP6V1B2TBXA2REDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894504-A | Inhalable formulation for treating bacterial infections in the lungs | 索米克生物技术有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-118340907-A | Polymer conjugates comprising bioactive agents | 波利艾克蒂瓦有限公司 | 2024-07-16 | — | — | CN | claimed |
| US-20230285572-A1 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC | 2023-09-14 | — | — | US | claimed |
| EP-4188433-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | Sepelo Therapeutics, LLC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| CN-110898061-B | An antibacterial agent suitable for oral administration to animals | 广州自远生物科技有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-109996804-B | Squalamine amide derivatives for the treatment of infections | 维克公司 | 2022-04-08 | — | — | CN | claimed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0027752-B1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1983-12-21 | — | — | EP | claimed |
| US-4341784-A | BACTERICIDES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1982-07-27 | — | — | US | claimed |
| EP-0027752-A1 | Naphthyridine derivatives, processes for their preparation and pharmaceutical compositions containing them | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1981-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | LMNA 2248/4885CYP2C9 98/4885ATP6V1B2 1340/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | LMNA 2248/4885CYP2C9 98/4885ATP6V1B2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.